GlassScriptPhysician profile
Guillermo A Ramirez
NPI 1720519838
$3,470.27
in general payments reported to CMS, 2019-2025
10 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $1,452 · 2024: $1,509 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $778.63 | 2023-2025 | Nuzyra |
| Abbvie INC. | $751.63 | 2022-2025 | |
| Shionogi INC | $673.02 | 2023-2025 | Fetroja |
| Melinta Therapeutics, LLC | $478.10 | 2023-2024 | Rezzayo, Vabomere, Kimyrsa |
| Viiv Healthcare Company | $298.28 | 2022-2024 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $133.70 | 2023-2024 | |
| La Jolla Pharmaceutical Company | $119.26 | 2022 | |
| Astellas Pharma US INC | $116.43 | 2023-2024 | Cresemba |
| Merck Sharp & Dohme LLC | $62.62 | 2023-2024 | Recarbrio, Dificid, Zerbaxa |
| Insmed, INC. | $58.60 | 2023-2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.